Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress. 2022

J Cedervall, and M Herre, and A Dragomir, and F Rabelo-Melo, and A Svensson, and C Thålin, and A Rosell, and V Hjalmar, and H Wallén, and H Lindman, and G Pejler, and E Hagström, and M Hultström, and A Larsson, and A K Olsson
Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Biomedical Center, Uppsala, Sweden.

Cancer is associated with systemic pathologies that contribute to mortality, such as thrombosis and distant organ failure. The aim of this study was to investigate the potential role of neutrophil extracellular traps (NETs) in myocardial inflammation and tissue damage in treatment-naïve individuals with cancer. Mice with mammary carcinoma (MMTV-PyMT) had increased plasma levels of NETs measured as H3Cit-DNA complexes, paralleled with elevated coagulation, compared to healthy littermates. MMTV-PyMT mice displayed upregulation of pro-inflammatory markers in the heart, myocardial hypertrophy and elevated cardiac disease biomarkers in the blood, but not echocardiographic heart failure. Moreover, increased endothelial proliferation was observed in hearts from tumor-bearing mice. Removal of NETs by DNase I treatment suppressed the myocardial inflammation, expression of cardiac disease biomarkers and endothelial proliferation. Compared to a healthy control group, treatment-naïve cancer patients with different malignant disorders had increased NET formation, which correlated to plasma levels of the inflammatory marker CRP and the cardiac disease biomarkers NT-proBNP and sTNFR1, in agreement with the mouse data. Altogether, our data indicate that NETs contribute to inflammation and myocardial stress during malignancy. These findings suggest NETs as potential therapeutic targets to prevent cardiac inflammation and dysfunction in cancer patients.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D009205 Myocarditis Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies. Carditis,Myocarditides
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D065206 Extracellular Traps Extracellular structure primarily composed of CHROMATIN and associated PROTEASES. Neutrophil Extracellular Traps,EEDTs (Eosinophil Extracellular DNA Traps),Eosinophil Extracellular DNA Traps,Eosinophil Extracellular Traps,Extracellular DNA Traps,NETs (Neutrophil Extracellular Traps),DNA Trap, Extracellular,DNA Traps, Extracellular,EEDT (Eosinophil Extracellular DNA Traps),Eosinophil Extracellular Trap,Extracellular DNA Trap,Extracellular Trap,Extracellular Trap, Eosinophil,Extracellular Trap, Neutrophil,Extracellular Traps, Eosinophil,Extracellular Traps, Neutrophil,NET (Neutrophil Extracellular Traps),Neutrophil Extracellular Trap,Trap, Eosinophil Extracellular,Trap, Extracellular,Trap, Extracellular DNA,Trap, Neutrophil Extracellular,Traps, Eosinophil Extracellular,Traps, Extracellular,Traps, Extracellular DNA,Traps, Neutrophil Extracellular

Related Publications

J Cedervall, and M Herre, and A Dragomir, and F Rabelo-Melo, and A Svensson, and C Thålin, and A Rosell, and V Hjalmar, and H Wallén, and H Lindman, and G Pejler, and E Hagström, and M Hultström, and A Larsson, and A K Olsson
July 2023, Cell communication and signaling : CCS,
J Cedervall, and M Herre, and A Dragomir, and F Rabelo-Melo, and A Svensson, and C Thålin, and A Rosell, and V Hjalmar, and H Wallén, and H Lindman, and G Pejler, and E Hagström, and M Hultström, and A Larsson, and A K Olsson
May 2022, Thrombosis research,
J Cedervall, and M Herre, and A Dragomir, and F Rabelo-Melo, and A Svensson, and C Thålin, and A Rosell, and V Hjalmar, and H Wallén, and H Lindman, and G Pejler, and E Hagström, and M Hultström, and A Larsson, and A K Olsson
February 2019, Oncotarget,
J Cedervall, and M Herre, and A Dragomir, and F Rabelo-Melo, and A Svensson, and C Thålin, and A Rosell, and V Hjalmar, and H Wallén, and H Lindman, and G Pejler, and E Hagström, and M Hultström, and A Larsson, and A K Olsson
October 2018, Hepatology (Baltimore, Md.),
J Cedervall, and M Herre, and A Dragomir, and F Rabelo-Melo, and A Svensson, and C Thålin, and A Rosell, and V Hjalmar, and H Wallén, and H Lindman, and G Pejler, and E Hagström, and M Hultström, and A Larsson, and A K Olsson
April 2020, JCI insight,
J Cedervall, and M Herre, and A Dragomir, and F Rabelo-Melo, and A Svensson, and C Thålin, and A Rosell, and V Hjalmar, and H Wallén, and H Lindman, and G Pejler, and E Hagström, and M Hultström, and A Larsson, and A K Olsson
March 2018, Oncotarget,
J Cedervall, and M Herre, and A Dragomir, and F Rabelo-Melo, and A Svensson, and C Thålin, and A Rosell, and V Hjalmar, and H Wallén, and H Lindman, and G Pejler, and E Hagström, and M Hultström, and A Larsson, and A K Olsson
January 2019, PloS one,
J Cedervall, and M Herre, and A Dragomir, and F Rabelo-Melo, and A Svensson, and C Thålin, and A Rosell, and V Hjalmar, and H Wallén, and H Lindman, and G Pejler, and E Hagström, and M Hultström, and A Larsson, and A K Olsson
April 2023, Experimental dermatology,
J Cedervall, and M Herre, and A Dragomir, and F Rabelo-Melo, and A Svensson, and C Thålin, and A Rosell, and V Hjalmar, and H Wallén, and H Lindman, and G Pejler, and E Hagström, and M Hultström, and A Larsson, and A K Olsson
February 2020, Oncotarget,
J Cedervall, and M Herre, and A Dragomir, and F Rabelo-Melo, and A Svensson, and C Thålin, and A Rosell, and V Hjalmar, and H Wallén, and H Lindman, and G Pejler, and E Hagström, and M Hultström, and A Larsson, and A K Olsson
May 2018, Cell death & disease,
Copied contents to your clipboard!